drugset / Trial / NCT02070991

Clinical Study to Evaluate the Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) Due to Left Ventricular Dysfunction

NCT02070991

Phase 2 Completed 63 enrolled Actelion
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Study to evaluate if macitentan is safe and tolerable enough to be used for treatment of subjects with combined pre- and post-capillary pulmonary hypertension (CpcPH) due to left ventricular dysfunction.

Timeline

Start
2014-07-01
Primary completion
2015-11-01
Completion
2015-11-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Macitentan Other / unclassified 10 mg Oral